top of page

Biosenta Inc. Achieves Major Breakthroughs in Bench Scale Production and Innovative Input Viability

TORONTO, ONTARIO / CALGARY, ALBERTA – June 10, 2024 – Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO), a leader in developing eco-friendly antimicrobial compounds, is pleased to announce significant advancements at its state-of-the-art bench scale production facility, which have exceeded all expectations. These breakthroughs not only demonstrate the capability of the bench scale facility but also mark the beginning of preparations for a commercial scale production facility.


Enhanced Production Capabilities

Under the guidance of Dr. Maen Husein, the bench scale facility has significantly exceeded performance expectations, affirming Biosenta's pathway towards scaling operations. The facility's production capacity has reached a remarkable 170 kg per day (10 hours/day), setting a solid foundation for the forthcoming design and fabrication of a commercial-scale production facility. “The novel solid feeding design has dramatically improved our production capabilities, ensuring efficient scalability as we advance,” commented Dr. Husein.

Introduction of Economical and Sustainable Inputs

In an innovative step forward, Biosenta has successfully utilized food-grade calcium hydroxide and industrial-grade carbon dioxide in the production of its flagship Tri-Filler® product. This initiative marks a significant reduction in production costs and environmental impact while maintaining the efficacy and high quality our customers expect from Tri-Filler®. “Adopting these food-grade materials reaffirms our commitment to environmental sustainability without compromising the effectiveness our customers rely on,” said Am Gill, CEO of Biosenta.


Strategic Implications and Investor Opportunities

These advancements offer substantial financial and operational benefits, providing clarity for cost modeling and projecting appealing margins for future investments. “We are now positioned to accelerate our transition from R&D to full commercialization, establishing a foundation that underscores our commitment to our investors and emphasizes our readiness for the upcoming phases,” Gill added.

About Biosenta Inc.

Biosenta Inc. develops innovative antimicrobial products that offer environmentally friendly solutions to a global market. Based in Toronto, Ontario, the company is dedicated to the advancement of technology that combats microbial growth in various materials. Biosenta’s flagship product, Tri-Filler®, represents a breakthrough in antimicrobial technology, providing durable protection against a wide spectrum of bacteria, molds, and fungi.


For further inquiries, please contact:

●       Am Gill, President and CEO, Biosenta Inc.


●       Phone:  416-410-2019


For more information, visit our website:

Forward-Looking Statements

This press release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”), including forward-looking statements relating the completion of the Transaction. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. If any such risks actually occur, they could impact the potential for discussion, agreement or completion of the Transaction and/or materially adversely affect the Company’s business, financial condition or results of operations. In that case, the trading price of the Company’s common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.



The CSE has in no way passed upon the contents of this news release and further, has neither approved nor disapproved of the contents of this news release. Neither the CSE nor its Regulation Services Provider (as such term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.



bottom of page